Letter to the Editor. Diagnosis of subarachnoid neurocysticercosis

Channel, Ivan Christian; Damara, Fachreza Aryo; Ramdhani, Alfya Nandika; Anton, Anton

doi:10.3171/2020.12.focus201006

Cited by 2 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As expected, both Ag-ELISA's report lower antigen levels in calcified lesions (mean of antigen ratio = 0.8), whereas patients with viable parenchymal cysts were positive, with higher antigen ratios (mean of antigen ratios = 1.8 for TsW8/TsW5 Ag-ELISA and 2.9 for B158/B60 Ag-ELISA). Subarachnoid NCC is known to commonly saturate the detection limit of the assay (mean of antigen ratios = 31.1 for TsW8/TsW5 Ag-ELISA, and 42.1 for B158/B60 Ag-ELISA) [37,38], which is also concordant for both assays. Interestingly, four positive samples from calcified NCC presented high antigen levels for both assays, suggesting a possible undetected viable lesion in the imaging diagnosis.…”

Section: Discussionmentioning

confidence: 64%

Consistent Measurement of Parasite-Specific Antigen Levels in Sera of Patients with Neurocysticercosis Using Two Different Monoclonal Antibody (mAb)-Based Enzyme-Linked Immunosorbent Assays

et al. 2023

View full text Add to dashboard Cite

Monoclonal antibody (mAb)-based enzyme-linked immunosorbent assay (ELISA) is a complementary diagnosis technique for neurocysticercosis (NCC), which detects circulating parasite antigen (Ag) indicative of viable infection and Ag levels that correlate well with the parasite burden. In this study, we compared the performance of two Ag-ELISA techniques for the detection of NCC. We assessed the agreement between our in-house TsW8/TsW5 Ag-ELISA and the widely used B158/B60 Ag-ELISA for measuring T. solium antigen levels in the sera from 113 patients with calcified, parenchymal, and subarachnoid NCC. Concordance was demonstrated evaluating the limits of agreement (LoAs) stratified by the type of NCC. Both ELISA’s detected 47/48 (97.8%) subarachnoid NCC cases. In parenchymal and calcified NCC, the B158/B60 Ag-ELISA detected 19/24 (79.2%) and 18/41 (43.9%) cases, while the TsW8/TsW5 Ag-ELISA detected 21/24 (87.5%) and 13/41 (31.7%), respectively. Parenchymal and calcified NCC obtained a perfect agreement (100%), indicating that all sample results were within the predicted LoA, while for subarachnoid NCC, the agreement was 89.6%. The high concordance between the assays was confirmed by Lin’s concordance coefficient (LCC = 0.97). Patients with viable parenchymal NCC (LCC = 0.95) obtained the highest concordance between assays, followed by subarachnoid NCC (LCC = 0.93) and calcified NCC (LCC = 0.92). The TsW8/TsW5 Ag-ELISA and B158/B60 Ag-ELISA showed high Ag measurement correlations across diverse types of NCC.

show abstract

Section: Discussionmentioning

confidence: 64%

Consistent Measurement of Parasite-Specific Antigen Levels in Sera of Patients with Neurocysticercosis Using Two Different Monoclonal Antibody (mAb)-Based Enzyme-Linked Immunosorbent Assays

et al. 2023

View full text Add to dashboard Cite

show abstract

From laboratory to clinical practice: an update of the immunological and molecular tools for neurocysticercosis diagnosis

Toribio,

Bustos,

Garcia

2024

Front. Parasitol.

View full text Add to dashboard Cite

Neurocysticercosis (NCC) is caused by the invasion of Taenia solium larvae in the central nervous system (CNS) and stands as the predominant cause of epilepsy and other neurological disorders in many developing nations. NCC diagnosis is challenging because it relies on brain imaging exams (CT or MRI), which are poorly available in endemic rural or resource-limited areas. Moreover, some NCC cases cannot be easily detected by imaging, leading to inconclusive results. Multiple laboratory assays, principally immunological, have been developed to support the diagnosis and/or monitor the treatment efficacy, but its production can be costly, laborious, and non-globally accessible because they depend on parasite material. Therefore, recent advances have been focused on the implementation of recombinant or synthetic antigens as well as monoclonal antibodies for NCC immunodiagnosis purposes. Similarly, molecular diagnosis has been explored, obtaining promising results. Here we described the recent progress in the development of immunological and molecular diagnostic tools for NCC diagnosis over the past 13 years, discussing their potential application to address important challenges and how to focus future directions to improve NCC diagnosis with emphasis on enhance accessibility and the importance of test validation to provide an adequate support for clinical decisions.

show abstract

Letter to the Editor. Diagnosis of subarachnoid neurocysticercosis

Cited by 2 publications

References 4 publications

Consistent Measurement of Parasite-Specific Antigen Levels in Sera of Patients with Neurocysticercosis Using Two Different Monoclonal Antibody (mAb)-Based Enzyme-Linked Immunosorbent Assays

Consistent Measurement of Parasite-Specific Antigen Levels in Sera of Patients with Neurocysticercosis Using Two Different Monoclonal Antibody (mAb)-Based Enzyme-Linked Immunosorbent Assays

From laboratory to clinical practice: an update of the immunological and molecular tools for neurocysticercosis diagnosis

Contact Info

Product

Resources

About